KMTS trades 20.4% below Wall Street's consensus target of $24.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes KMTS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 22, 2026, KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) has a Wall Street consensus price target of $24.00, based on estimates from 4 covering analysts. With the stock currently trading at $19.93, this represents a potential upside of +20.4%. The company has a market capitalization of $1.16B.
Analyst price targets range from a low of $24.00 to a high of $24.00, representing a 0% spread in expectations. The median target of $24.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, KMTS trades at a trailing P/E of -3.9x. Analysts expect EPS to grow +14.5% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
MDTMedtronic plc | $101.9B | $79.34 | $95.80 | +20.7% | Buy | 13.3x | 51 |
ABTAbbott Laboratories | $153.7B | $88.38 | $127.46 | +44.2% | Buy | 16.1x | 41 |
BSXBoston Scientific Corporation | $67.3B | $45.29 | $82.90 | +83.0% | Buy | 13.5x | 44 |
EWEdwards Lifesciences Corporation | $50.4B | $87.36 | $96.55 | +10.5% | Buy | 29.0x | 48 |
LIVNLivaNova PLC | $4.3B | $78.50 | $79.86 | +1.7% | Buy | 18.5x | 14 |
NVCRNovoCure Limited | $1.6B | $14.28 | $33.00 | +131.1% | Buy | — | 15 |
AVNSAvanos Medical, Inc. | $1.2B | $24.94 | $23.00 | -7.8% | Hold | 24.9x | 8 |
IRTCiRhythm Technologies, Inc. | $3.4B | $104.65 | $188.75 | +80.4% | Buy | — | 20 |
BEATHeartBeam, Inc. | $26M | $0.76 | — | — | — | — | — |
TXNTexas Instruments Incorporated | $294.0B | $322.86 | $274.06 | -15.1% | Buy | 41.9x | 65 |
Quick answers to the most common questions about buying KMTS stock.
The consensus Wall Street price target for KMTS is $24, representing 20.4% upside from the current price of $19.93. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
KMTS has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $24 implies 20.4% upside from current levels.
KMTS's current price is $19.93 with a consensus target of $24 (20.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $24 for KMTS, while the most conservative target is $24. The consensus of $24 represents the median expectation. These targets typically reflect 12-month expectations.
KMTS is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month KMTS stock forecast based on 4 Wall Street analysts shows a consensus price target of $24, with estimates ranging from $24 (bear case) to $24 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on KMTS, with a "Buy" consensus rating and $24 price target (20.4% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
KMTS analyst price targets range from $24 to $24, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $24 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.